VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Scott on Connect MDS and AML: A Disease Registry

Bart L. Scott, MD
Published: Thursday, Apr 30, 2015



Bart L. Scott, assistant member, clinical research division, Fred Hutchinson Cancer Research Center, discusses a new registry that will collect data from patients with MDS.

Scott says this large, national registry will collect information on biological markers and prognostic markers from patients with MDS. From this registry, researchers will be able to get a better idea of how to predict long-term outcomes. The registry will also include patient samples, Scott says, so that researchers can look at a variety of factors that can be involved in prognosis and response to different types of treatments.

<<< View more from the 2015 MDS Symposium



Bart L. Scott, assistant member, clinical research division, Fred Hutchinson Cancer Research Center, discusses a new registry that will collect data from patients with MDS.

Scott says this large, national registry will collect information on biological markers and prognostic markers from patients with MDS. From this registry, researchers will be able to get a better idea of how to predict long-term outcomes. The registry will also include patient samples, Scott says, so that researchers can look at a variety of factors that can be involved in prognosis and response to different types of treatments.

<<< View more from the 2015 MDS Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x